Augusto_Valdivia

Medical Oncologist
Thoracic Cancer Unit - Vall d'Hebron Institute of Oncology

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

💬 “Tots vam somiar una mica a fer una oncologia d’excel·lència per als nostres pacients.”

@EnriquetaFelip, codirectora de Recerca Clínica i cap del Grup de Tumors Toràcics del #VHIO, parla de medicina de precisió, treball en equip i recerca orientada als pacients.

▶️ Vídeo complet a YouTube
➕ https://t.co/CEk5k6qTNl

#20VHIO @vallhebron

[Augusto_Valdivia @Augusto_AVB]

@windscribecom

[Grupo Español de Cáncer de Pulmón @gecp_org]

👉Seguimos avanzando con el #XIVCursoCompetenciasGECP.

Gracias a los docentes que están participando por compartir su experiencia, conocimiento y compromiso con la formación.

¡Un placer seguir aprendiendo juntos!

@Annestival @bmassutis @ManuelDomine @ECarcereny

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🚨 Key issues w/ @NatureMedicine time-of-day IO paper:
• Protocol v1 (Jan 2022) cites 2024 refs → timeline error
• https://t.co/EURNLUgMgw record changed: randomized → observational → revised
• Protocol-registry mismatch (endpoints, n, ECOG, Tx)
• OS K-M curve errors (censor marks ≠ at-risk table)
• Unusually smooth PFS w/ 6-wk scans
• Median OS CI “NE” despite est. median; Table 1 p-val inconsistencies

🧭 Questioned methods need full transparency & clarification to restore trust.

[César Serrano García @DrCeSarcoma]

👋 Hi #sarcoma twitter community

Just wanted to share that I will serve as @JCO_ASCO Editorial Board member 2026-2028

💊 I am looking forward to receiving high-quality papers on sarcoma clinical research!

https://t.co/HelxBBHmNO

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

I am going to continue to fight for this. All government/public funded research should by default be open access. Such an important trial- funded by public money- cannot stay behind a paywall. Public funded the research, now they should pay to read the results? Doesn't make sense. https://t.co/Dmxpz1NS2B

[Augusto_Valdivia @Augusto_AVB]

@DrRishabhOnco Can you give the references?

[Augusto_Valdivia @Augusto_AVB]

@aditharun_ @Sadagopan_A Can you send bibliography? Thanks!

[César Serrano García @DrCeSarcoma]

In my humble opinion, the next generation of reviews must be more forward-thinking and give personal views on the topic. This would make our works truly unique

By the way: everyone shows their concerns with AI, but not with medical writers taking over our duty of writing science

[Roberto Ferrara @RobertoFerrara_]

Deeply diving into 'seed and soil' model with @SonyaHessey.
- 'Source' mets (met to met) occur early in NSCLC.
-Extrathorax mets derive mainly from extrathoracic seeding clones
-Intrathoracic clones with extrathorax seeding capacity have higher chromosomal instability #ESMOMAP

[Augusto_Valdivia @Augusto_AVB]

@Facundo59204769 Link?

[Oncobites.tv @OncobitesTv]

🌐 Desde #ESMO25, seguimos cubriendo el congreso con el Dr. David Illescas una entrevista clave sobre los avances presentados. 🎥 Sigue toda la cobertura en tiempo real en nuestro canal: https://t.co/GUoJgNZAyA
#Oncología #ESMO2025 #InvestigaciónMédica #Cáncer #OncoBites #CongresoOncológico

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Want a quick update on what happened yesterday? Come join us for Highlights of the Day session! 🤩

Plus you get to wear some cool 🎧

✨Happening now, in the E poster hall, with @EnriquetaFelip @BenjaminBesseMD Drs. Rafal Dziadziuszko, Fernando Lopez Rio

#WCLC25 @IASLC

[Vall d'Hebron @vallhebron]

.@telediario_tve entrevista Pilar, pacient de càncer de pulmó: la Dra. @EnriquetaFelip, cap d'Oncologia Mèdica de l'hospital #VallHebron i cap del Grup de Tumors Toràcics i Càncer de Cap i Coll del @VHIO, i la Dra. Patricia Iranzo, investigadora del @VHIO, parlen de la malaltia.

[Augusto_Valdivia @Augusto_AVB]

@raffcolo Dear Raffaelle, could the ammonia (NH3) reported be the cause of ILD before it is turned into NH4+?

[Erman Akkus @Erman_Akkus]

🧬 Acquired resistance to RAS inhibitors in pancreatic cancer
@Annals_Oncology

✅Insightful data by @Florian_Castet @vicenttianfr @MacarullaTeresa

➡️Common genetic resistant mechanisms with daraxonrasib and G12Ci
❗️Disease site and drug specifity ➡️ resistance mechanism ➡️ combination and sequence of treatments

👉https://t.co/Qjrej7Kodm

@myESMO #cancer #oncology #MedX #pancreatic

[IASLC @IASLC]

The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, @StephenVLiu, @EnriquetaFelip & @nievamd discuss this approval & how to position taletrectinib among treatment options.

🎧 https://t.co/NmacJQBoIn

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🚀 As part of @I3lung, VHIO joins the Annual Meeting, leading the way towards personalized oncology through #AI.

The Thoracic Tumors Group, led by @EnriquetaFelip, plays a key role by contributing clinical expertise and leading genomic analysis in this EU-funded initiative revolutionizing lung cancer treatment.

👉 https://t.co/vizRxThLq6

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

Presented at #ASCO25 and published in @NEJM: Tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improves overall survival vs chemo in 2L #SCLC (13.6 vs 8.3 mo).

👏 Congrats to VHIO's researcher @pedrofsrocha for contributing to this pivotal trial ‼️

➡️ https://t.co/p3jo4nuKLH

[Grupo Español de Cáncer de Pulmón @gecp_org]

¡Hoy cerramos el 13º Curso de Competencias en Cáncer de Pulmón! 🫁

👉Han sido dos días de aprendizaje intensivo con 12 docentes y la participación de 60 residentes y adjuntos. ¡Gracias a todos por hacerlo posible!

#CáncerDePulmón #CursoCompetencias2025